<DOC>
	<DOCNO>NCT00779337</DOCNO>
	<brief_summary>This trial use new method treat lymphoma use therapy derive person 's Killer T cell . These Killer T cell take person 's blood grown test tube increase number cell specifically active lymphoma cell . The cell give patient intravenous infusion aim kill lymphoma cell . Potentially treatment help kill residual/recurrent tumour present lymphoma treatment reduce chance tumour recur .</brief_summary>
	<brief_title>Epstein-Barr Virus ( EBV ) -Specific T Cells Therapy Relapsed/Refractory EBV-positive Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Informed consent . EBVpositive lymphoma determine situ hybridization equivalent ( exclude Burkitts Lymphoma ) . Age 18 year old . ECOG performance status 1 , 2 3 Life expectancy least 6 month . Measurable disease : either relapse , partially responsive , refractory progressive disease , include disease detect either clinical examination , radiographic evaluation ( include CT scan , physician 's discretion functional imaging ) , persistently detectable plasma EBV viral load . No chemotherapy / radiotherapy and/or antibody therapy least 2 week prior anticipated date first infusion . EBV negative tumour Presence detectable malignant cell peripheral circulation flow cytometry morphology Serious infection within past 28 day adequately respond therapy Pregnancy , unwilling use adequate contraception Serology ( take within 3 month CTL release date ) indicate active HBV HCV infection , positive serology HIV I &amp; II , HTLV1 syphilis Negative serology EBV Psychiatric , addictive condition may compromise ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Epstein-Barr virus</keyword>
	<keyword>lymphoma</keyword>
	<keyword>immunotherapy</keyword>
</DOC>